Clinical Trials / Research Studies

ATRT

PEPN2121: Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

• Ages: 12 Months and older

This phase I/II trial studies how well tiragolumab and atezolizumab works when given to children and adults with SMARCB1 or SMARCA4 deficient tumors that that has either come back (relapsed) or does not respond to therapy (refractory). SMARCB1 or SMARCA4 deficiency means that tumor cells are missing ...More

SMARCA4 Gene Study

Cincinnati Children’s is conducting a research study, also known as a clinical trial, to learn more about the risk of developing cancer in individuals who carry disease-causing changes (mutations) in the SMARCA4 gene. These changes, which can be inherited from a parent, may lead to rare cancer ...More